---
layout: default
title: Docetaxel
description: "Docetaxel çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æœ€é«˜è­‰æ“šç­‰ç´š L1ï¼ŒåŒ…å« 10 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: é«˜è­‰æ“šç­‰ç´š (L1-L2)
nav_order: 61
evidence_level: L1
indication_count: 10
---

# Docetaxel

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L1</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>10</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Docetaxelï¼šå¾HER2é™½æ€§ä¹³ç™Œåˆ°å¥³æ€§ä¹³è…ºç™Œ

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Docetaxel å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Docetaxel åŸæœ¬ç”¨æ–¼æ²»ç™‚ HER2 é™½æ€§ä¹³ç™ŒåŠè½‰ç§»æ€§èƒƒç™Œã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**å¥³æ€§ä¹³è…ºç™Œ (female breast carcinoma)** æœ‰æ•ˆï¼Œ
ç›®å‰æœ‰ **è¶…é50å€‹è‡¨åºŠè©¦é©—**å’Œ **å¤šç¯‡æ–‡ç»**æ”¯æŒé€™å€‹æ–¹å‘ã€‚
</p>

## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | HER2é™½æ€§æ—©æœŸä¹³ç™Œã€è½‰ç§»æ€§ä¹³ç™Œã€è½‰ç§»æ€§èƒƒç™Œ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | å¥³æ€§ä¹³è…ºç™Œã€Ewing sarcomaã€well-differentiated fetal adenocarcinoma of the lungã€small cell lung carcinomaã€primary pulmonary lymphomaã€botryoid-type embryonal rhabdomyosarcoma of the vaginaã€pulmonary blastomaã€rhabdomyosarcoma (disease)ã€embryonal extrahepatic bile duct rhabdomyosarcomaã€parameningeal embryonal rhabdomyosarcoma |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.90% |
| è­‰æ“šç­‰ç´š | L1 |
| å°ç£ä¸Šå¸‚ | å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | å¤šå¼µ |
| å»ºè­°æ±ºç­– | Proceed |



## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. female breast carcinoma</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.90%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content">

<h3>ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ</h3>

<p><p class="key-answer" data-question="é€™å€‹è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰æ˜¯ä»€éº¼ï¼Ÿ"></p>
<p>Docetaxel å±¬æ–¼ taxane é¡æŠ—è…«ç˜¤è—¥ç‰©ï¼Œé€éä¿ƒé€²å¾®ç®¡è›‹ç™½èšåˆä¸¦æŠ‘åˆ¶å¾®ç®¡è§£èšä¾†å¹²æ“¾ç´°èƒåˆ†è£‚ï¼Œ</p>
<p>å°è‡´ç´°èƒé€±æœŸåœæ»¯åœ¨ G2/M æœŸã€‚å…¶åœ¨ä¹³ç™Œæ²»ç™‚ä¸­çš„ç™‚æ•ˆå·²è¢«å»£æ³›è­‰å¯¦ï¼Œ</p>
<p>åŒ…æ‹¬èˆ‡ trastuzumabã€carboplatin ç­‰è—¥ç‰©ä½µç”¨çš„å¤šç¨®æ²»ç™‚æ–¹æ¡ˆã€‚</p>
<p>é æ¸¬å…¶å°å¥³æ€§ä¹³è…ºç™Œæœ‰æ•ˆå…·æœ‰æ˜ç¢ºçš„æ©Ÿè½‰åŸºç¤ã€‚</p>
<p></p></p>

<p><div class="key-takeaway"></p>
<p>æ­¤é æ¸¬åŸºæ–¼è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰ï¼Œèˆ‡ç¾æœ‰è‡¨åºŠè­‰æ“šæ–¹å‘ä¸€è‡´ã€‚</p>

<h3>è‡¨åºŠè©¦é©—</h3>

<table>
<thead>
<tr>
<th>è©¦é©—ç·¨è™Ÿ</th>
<th>éšæ®µ</th>
<th>ç‹€æ…‹</th>
<th>äººæ•¸</th>
<th>ä¸»è¦ç™¼ç¾</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT00002707">NCT00002707</a></td>
<td>Phase 3</td>
<td>COMPLETED</td>
<td>2411</td>
<td>æ¯”è¼ƒè¡“å‰ AC åŒ–ç™‚åˆä½µ docetaxel çš„æ•ˆæœ</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT03588091">NCT03588091</a></td>
<td>Phase 3</td>
<td>COMPLETED</td>
<td>355</td>
<td>è©•ä¼° pyrotinib è¯åˆ trastuzumab å’Œ docetaxel çš„æ–°è¼”åŠ©æ²»ç™‚</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT01583426">NCT01583426</a></td>
<td>Phase 3</td>
<td>COMPLETED</td>
<td>1229</td>
<td>æ¯”è¼ƒ nab-paclitaxel èˆ‡ solvent-based paclitaxel ä½œç‚ºæ–°è¼”åŠ©åŒ–ç™‚</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT00887536">NCT00887536</a></td>
<td>Phase 3</td>
<td>COMPLETED</td>
<td>1613</td>
<td>æ¯”è¼ƒ TC+bevacizumab èˆ‡ TC åŠ TAC åœ¨ HER2 é™°æ€§ä¹³ç™Œçš„è¼”åŠ©æ²»ç™‚</td>
</tr>
<tr>
<td><a href="https://clinicaltrials.gov/study/NCT00047255">NCT00047255</a></td>
<td>Phase 3</td>
<td>COMPLETED</td>
<td>263</td>
<td>æ¯”è¼ƒ docetaxel+trastuzumab èˆ‡ docetaxel+carboplatin+trastuzumab</td>
</tr>
</tbody>
</table>

<h3>ç›¸é—œæ–‡ç»</h3>

<table>
<thead>
<tr>
<th>PMID</th>
<th>å¹´ä»½</th>
<th>é¡å‹</th>
<th>æœŸåˆŠ</th>
<th>ä¸»è¦ç™¼ç¾</th>
</tr>
</thead>
<tbody>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/28398846/">28398846</a></td>
<td>2017</td>
<td>RCT</td>
<td>J Clin Oncol</td>
<td>ABC è©¦é©—æ¯”è¼ƒ TC èˆ‡ TaxAC æ–¹æ¡ˆåœ¨æ—©æœŸä¹³ç™Œçš„ç™‚æ•ˆ</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/7595719/">7595719</a></td>
<td>1995</td>
<td>Review</td>
<td>J Clin Oncol</td>
<td>Docetaxel çš„è‡¨åºŠå‰å’Œè‡¨åºŠæ¦‚è¿°</td>
</tr>
<tr>
<td><a href="https://pubmed.ncbi.nlm.nih.gov/27997437/">27997437</a></td>
<td>2016</td>
<td>Cohort</td>
<td>N/A</td>
<td>Docetaxel åŒ–ç™‚èˆ‡ä¹³ç™Œç›¸é—œæ·‹å·´æ°´è…«çš„é—œè¯</td>
</tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. Ewing sarcoma</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.90%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ13 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00014456" target="_blank">NCT00014456</a></td><td>PHASE1</td><td>COMPLETED</td><td>35</td><td>A Dose-Escalation Trial Of The Combination Of Docetaxel, Gemcitabine And Filgras...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04183062" target="_blank">NCT04183062</a></td><td>PHASE2</td><td>WITHDRAWN</td><td>0</td><td>A Phase 2 Study of the Safety and Efficacy of BIO-11006 in the Treatment of Recu...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06669013" target="_blank">NCT06669013</a></td><td>PHASE3</td><td>RECRUITING</td><td>40</td><td>A Randomized, Multicenter, Open-label Phase III Study of Dinutuximab Beta With I...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT02511132" target="_blank">NCT02511132</a></td><td>PHASE2</td><td>COMPLETED</td><td>22</td><td>A 2-part Trial Comparing Overall Survival of Patients With Metastatic Ewing&#x27;s Sa...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00049296" target="_blank">NCT00049296</a></td><td>PHASE1</td><td>COMPLETED</td><td>26</td><td>Phase I Pharmacokinetic Trial of Thalidomide and Docetaxel: A Regimen Based on A...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 8 é …è©¦é©—</em></p>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28787430/" target="_blank">28787430</a></td><td>2017</td><td>Article</td><td>British journal of c</td><td>GEIS-21: a multicentric phase II study of intensive chemothe...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/25164234/" target="_blank">25164234</a></td><td>2014</td><td>Article</td><td>BMC cancer</td><td>A study of docetaxel and irinotecan in children and young ad...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35023660/" target="_blank">35023660</a></td><td>2021</td><td>Article</td><td>The Turkish journal </td><td>Primary spinal multifocal intradural-extramedullary Ewing sa...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32386107/" target="_blank">32386107</a></td><td>2020</td><td>Article</td><td>Pediatric blood &amp; ca</td><td>Phase II trial of gemcitabine and nab-paclitaxel in patients...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/28221727/" target="_blank">28221727</a></td><td>2017</td><td>Article</td><td>Pediatric blood &amp; ca</td><td>Docetaxel, bevacizumab, and gemcitabine for very high risk s...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. well-differentiated fetal adenocarcinoma of the lung</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.84%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ1 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/23750171/" target="_blank">23750171</a></td><td>2013</td><td>Article</td><td>Tuberculosis and res</td><td>A case of locally advanced well-differentiated fetal adenoca...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">4. small cell lung carcinoma</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.83%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ50 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00903292" target="_blank">NCT00903292</a></td><td>NA</td><td>UNKNOWN</td><td>52</td><td>Tailored Second Line Treatment by EGFR Mutation in Patients With Advanced Lung A...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03304093" target="_blank">NCT03304093</a></td><td>PHASE2</td><td>COMPLETED</td><td>30</td><td>Immunotherapy by Nivolumab After Prior Chemotherapy for HIV+ Patients With Advan...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00051974" target="_blank">NCT00051974</a></td><td>PHASE2</td><td>COMPLETED</td><td>155</td><td>A Randomized, Multicenter, Open-Label, Phase 2 Study of VELCADE Alone or VELCADE...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT01891123" target="_blank">NCT01891123</a></td><td>NA</td><td>UNKNOWN</td><td>300</td><td>An Open-label Randomized Clinical Trial to Compare the Toxicities and Efficacy o...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04747470" target="_blank">NCT04747470</a></td><td>PHASE1</td><td>TERMINATED</td><td>13</td><td>A Phase 1b Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacok...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 45 é …è©¦é©—</em></p>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ20 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37196428/" target="_blank">37196428</a></td><td>2023</td><td>Article</td><td>Journal of clinical </td><td>Flashback Foreword: Docetaxel Versus Best Supportive Care in...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36773042/" target="_blank">36773042</a></td><td>2023</td><td>Article</td><td>European journal of </td><td>Sequencing strategies with ramucirumab and docetaxel followi...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37945672/" target="_blank">37945672</a></td><td>2023</td><td>Article</td><td>Scientific reports</td><td>Detection of factors related to treatment reduction in docet...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/20038723/" target="_blank">20038723</a></td><td>2010</td><td>Article</td><td>Journal of clinical </td><td>Molecular predictors of outcome with gefitinib and docetaxel...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/39434017/" target="_blank">39434017</a></td><td>2024</td><td>Article</td><td>BMC cancer</td><td>Effect of baseline anemia on the efficacy of docetaxel and r...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 15 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">5. primary pulmonary lymphoma</span>
<span class="evidence-badge evidence-L1">L1</span>
<span class="prediction-score">99.83%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ8 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03884556" target="_blank">NCT03884556</a></td><td>PHASE1</td><td>COMPLETED</td><td>56</td><td>Phase 1/1b Study of the Safety of TTX-030 as a Single Agent and in Combination W...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05094336" target="_blank">NCT05094336</a></td><td>PHASE1, PHASE2</td><td>ACTIVE_NOT_RECRUITING</td><td>329</td><td>A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Phar...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06074588" target="_blank">NCT06074588</a></td><td>PHASE3</td><td>RECRUITING</td><td>556</td><td>A Randomized, Open-label, Phase 3 Study of MK-2870 vs Chemotherapy (Docetaxel or...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03611738" target="_blank">NCT03611738</a></td><td>PHASE1</td><td>ACTIVE_NOT_RECRUITING</td><td>21</td><td>Phase I Study of Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCL...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT00049296" target="_blank">NCT00049296</a></td><td>PHASE1</td><td>COMPLETED</td><td>26</td><td>Phase I Pharmacokinetic Trial of Thalidomide and Docetaxel: A Regimen Based on A...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 3 é …è©¦é©—</em></p>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ18 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/23724913/" target="_blank">23724913</a></td><td>2013</td><td>Article</td><td>The New England jour</td><td>Crizotinib versus chemotherapy in advanced ALK-positive lung...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37593227/" target="_blank">37593227</a></td><td>2023</td><td>Article</td><td>EClinicalMedicine</td><td>AK112, a novel PD-1/VEGF bispecific antibody, in combination...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/19879424/" target="_blank">19879424</a></td><td>2009</td><td>Article</td><td>Advances in cancer r</td><td>Clusterin and chemoresistance.</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/32529467/" target="_blank">32529467</a></td><td>2020</td><td>Article</td><td>Investigational new </td><td>A randomized, double-blind, placebo-controlled study of B-ce...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/31023244/" target="_blank">31023244</a></td><td>2019</td><td>Article</td><td>BMC cancer</td><td>Comparative survival benefit of currently licensed second or...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 13 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">6. botryoid-type embryonal rhabdomyosarcoma of the vagina</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.80%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">7. pulmonary blastoma</span>
<span class="evidence-badge evidence-L4">L4</span>
<span class="prediction-score">99.80%</span>
</summary>
<div class="indication-content">

<h3>ç›¸é—œæ–‡ç»ï¼ˆ3 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/38835107/" target="_blank">38835107</a></td><td>2024</td><td>Article</td><td>The Journal of inter</td><td>Pulmonary blastoma with a good prognosis: a case report and ...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/41626175/" target="_blank">41626175</a></td><td>2025</td><td>Article</td><td>Frontiers in oncolog</td><td>Exceptional long-term survival in an adult with advanced cla...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/23750171/" target="_blank">23750171</a></td><td>2013</td><td>Article</td><td>Tuberculosis and res</td><td>A case of locally advanced well-differentiated fetal adenoca...</td></tr>
</tbody>
</table>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">8. rhabdomyosarcoma (disease)</span>
<span class="evidence-badge evidence-L2">L2</span>
<span class="prediction-score">99.79%</span>
</summary>
<div class="indication-content">

<h3>è‡¨åºŠè©¦é©—ï¼ˆ6 é …ï¼‰</h3>

<table>
<thead>
<tr><th>è©¦é©—ç·¨è™Ÿ</th><th>éšæ®µ</th><th>ç‹€æ…‹</th><th>äººæ•¸</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://clinicaltrials.gov/study/NCT04906876" target="_blank">NCT04906876</a></td><td>PHASE2</td><td>WITHDRAWN</td><td>0</td><td>A Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3Î²) Inhibito...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT06669013" target="_blank">NCT06669013</a></td><td>PHASE3</td><td>RECRUITING</td><td>40</td><td>A Randomized, Multicenter, Open-label Phase III Study of Dinutuximab Beta With I...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05116800" target="_blank">NCT05116800</a></td><td>PHASE2</td><td>WITHDRAWN</td><td>0</td><td>A Phase 2 Study of 9-ING-41, a Glycogen Synthase Kinase-3 Beta (GSK-3Î²) Inhibito...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT03524898" target="_blank">NCT03524898</a></td><td>PHASE1, PHASE2</td><td>TERMINATED</td><td>39</td><td>NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma. A Multic...</td></tr>
<tr><td><a href="https://clinicaltrials.gov/study/NCT05634369" target="_blank">NCT05634369</a></td><td>PHASE1, PHASE2</td><td>RECRUITING</td><td>50</td><td>A Multi-Institution Study of TGFÎ² Imprinted, Ex Vivo Expanded Universal Donor NK...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 1 é …è©¦é©—</em></p>

<h3>ç›¸é—œæ–‡ç»ï¼ˆ9 ç¯‡ï¼‰</h3>

<table>
<thead>
<tr><th>PMID</th><th>å¹´ä»½</th><th>é¡å‹</th><th>æœŸåˆŠ</th><th>ä¸»è¦ç™¼ç¾</th></tr>
</thead>
<tbody>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/22302783/" target="_blank">22302783</a></td><td>2012</td><td>Article</td><td>Pediatric blood &amp; ca</td><td>Gemcitabine and docetaxel (GEMDOX) for the treatment of rela...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/37422615/" target="_blank">37422615</a></td><td>2023</td><td>Article</td><td>BMC cancer</td><td>A phase II study of gemcitabine and docetaxel combination in...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36119541/" target="_blank">36119541</a></td><td>2022</td><td>Article</td><td>Frontiers in oncolog</td><td>Embryonic esophageal rhabdomyosarcoma in an adult male: A ca...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/35529801/" target="_blank">35529801</a></td><td>2022</td><td>Article</td><td>Journal of kidney ca</td><td>Primary Rhabdomyosarcoma of Kidney with Local Recurrence and...</td></tr>
<tr><td><a href="https://pubmed.ncbi.nlm.nih.gov/36890471/" target="_blank">36890471</a></td><td>2023</td><td>Article</td><td>BMC cancer</td><td>Protocol for the 2ND-STEP study, Japan Clinical Oncology Gro...</td></tr>
</tbody>
</table>
<p><em>...åŠå…¶ä»– 4 ç¯‡æ–‡ç»</em></p>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">9. embryonal extrahepatic bile duct rhabdomyosarcoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.76%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">10. parameningeal embryonal rhabdomyosarcoma</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.76%</span>
</summary>
<div class="indication-content">

<div class="no-evidence-notice">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„å°ˆé–€è‡¨åºŠç ”ç©¶ã€‚æ­¤ç‚º TxGNN æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| å¤šå¼µè¨±å¯è­‰ | æ›²æ–¯è‹¥å‡æ™¶æ³¨å°„åŠ‘150æ¯«å…‹ | æ³¨å°„åŠ‘ | HER2é™½æ€§æ—©æœŸä¹³ç™Œè¼”åŠ©æ²»ç™‚ã€è½‰ç§»æ€§ä¹³ç™Œã€è½‰ç§»æ€§èƒƒç™Œ |

## ç´°èƒæ¯’æ€§

| é …ç›® | å…§å®¹ |
|------|------|
| ç´°èƒæ¯’æ€§åˆ†é¡ | å‚³çµ±ç´°èƒæ¯’æ€§è—¥ç‰© (Taxaneé¡) |
| éª¨é«“æŠ‘åˆ¶é¢¨éšª | é«˜åº¦ (å—œä¸­æ€§ç™½è¡€çƒæ¸›å°‘ç‚ºä¸»è¦æ¯’æ€§) |
| è‡´åæ€§åˆ†ç´š | ä½åº¦ |
| ç›£æ¸¬é …ç›® | CBCï¼ˆå«åˆ†é¡ï¼‰ã€è‚åŠŸèƒ½ã€å‘¨é‚Šç¥ç¶“ç—…è®Š |
| è™•ç½®é˜²è­· | éœ€ä¾ç´°èƒæ¯’æ€§è—¥ç‰©è™•ç½®è¦ç¯„æ“ä½œ |

## å®‰å…¨æ€§è€ƒé‡

- **ä¸»è¦ä¸è‰¯åæ‡‰**ï¼šå—œä¸­æ€§ç™½è¡€çƒæ¸›å°‘ã€éæ•åæ‡‰ã€å‘¨é‚Šç¥ç¶“ç—…è®Šã€æ¶²é«”æ»¯ç•™
- **é é˜²æªæ–½**ï¼šéœ€é å…ˆçµ¦äºˆ dexamethasone ä»¥æ¸›å°‘æ¶²é«”æ»¯ç•™å’Œéæ•åæ‡‰




### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**è‘¡è„æŸšæ±** ğŸŸ¢ Minor
- å½±éŸ¿ï¼šå½±éŸ¿è—¥ç‰©ä»£è¬ã€‚å¯èƒ½å¢åŠ è—¥ç‰©è¡€ä¸­æ¿ƒåº¦ã€‚
- å»ºè­°ï¼šé¿å…å¤§é‡æ”å–ã€‚éœ€ç›£æ¸¬ç™‚æ•ˆæˆ–ä¸è‰¯åæ‡‰ã€‚é¿å…é£Ÿç”¨è‘¡è„æŸšæˆ–è‘¡è„æŸšæ±ã€‚

### è—¥ç‰©-è‰è—¥äº¤äº’ä½œç”¨ (DHI)

**è–ç´„ç¿°è‰ï¼ˆè²«è‘‰é€£ç¿¹ï¼‰** ğŸ”´ Major
- å½±éŸ¿ï¼šè–ç´„ç¿°è‰é™ä½åŒ–ç™‚è—¥ç‰©ç™‚æ•ˆ
- å»ºè­°ï¼šåŒ–ç™‚æœŸé–“ç¦ç”¨æ‰€æœ‰è‰è—¥è£œå……å“


### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a>ï¼ˆåŸæ–‡å…§å®¹è«‹åƒé–±è©²ç¶²ç«™ï¼‰</div>

**Alcoholism** ğŸŸ¡ Moderate
- éœ€å®šæœŸç›£æ¸¬ã€‚

**Paresthesia** ğŸŸ¡ Moderate
- å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚å‡ºç¾ç—‡ç‹€æ™‚æ‡‰è€ƒæ…®åœè—¥ã€‚

**Infections** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚éœ€å®šæœŸç›£æ¸¬ã€‚é¢¨éšªåŒ…æ‹¬ï¼šéª¨é«“æŠ‘åˆ¶ã€æ„ŸæŸ“ã€‚

**Edema** ğŸŸ¢ Minor
- å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

**Eye Diseases** ğŸŸ¢ Minor
- å¿…è¦æ™‚æ‡‰åœæ­¢æ²»ç™‚ã€‚

**è‚è‡Ÿç–¾ç—…** ğŸŸ¢ Minor
- ä¸æ‡‰ä½¿ç”¨æœ¬è—¥ç‰©ã€‚å¯èƒ½æœ‰è‡´å‘½é¢¨éšªã€‚

**Bone Marrow Failure Disorders** ğŸŸ¢ Minor
- æœ¬è—¥ç‰©åœ¨æ­¤æƒ…æ³ä¸‹ç¦ç”¨ã€‚é¢¨éšªåŒ…æ‹¬ï¼šéª¨é«“æŠ‘åˆ¶ã€æ„ŸæŸ“ã€è¡€æ “ã€è²§è¡€ã€‚å¯èƒ½æœ‰åš´é‡ä¸è‰¯åæ‡‰ã€‚

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šProceed**

**ç†ç”±ï¼š**
Docetaxel åœ¨å¥³æ€§ä¹³è…ºç™Œçš„è‡¨åºŠæ‡‰ç”¨å·²æœ‰å¤§é‡ Phase 3 è©¦é©—æ”¯æŒï¼Œç™‚æ•ˆè­‰æ“šå……åˆ†ï¼Œ
ä¸”ä½œç”¨æ©Ÿè½‰èˆ‡é æ¸¬é©æ‡‰ç—‡é«˜åº¦ç›¸é—œã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- é‡å°ç‰¹å®šä¹³ç™Œäºå‹çš„ç²¾æº–æ²»ç™‚æ–¹æ¡ˆå„ªåŒ–
- æ¸›å°‘å‘¨é‚Šç¥ç¶“ç—…è®Šç­‰é•·æœŸæ¯’æ€§çš„ç­–ç•¥ç ”ç©¶

---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Temozolomide]({{ "/drugs/temozolomide/" | relative_url }}) - è­‰æ“šç­‰ç´š L1
- [Anastrozole]({{ "/drugs/anastrozole/" | relative_url }}) - è­‰æ“šç­‰ç´š L1
- [Icatibant]({{ "/drugs/icatibant/" | relative_url }}) - è­‰æ“šç­‰ç´š L1
- [Naftifine]({{ "/drugs/naftifine/" | relative_url }}) - è­‰æ“šç­‰ç´š L1
- [Ipratropium]({{ "/drugs/ipratropium/" | relative_url }}) - è­‰æ“šç­‰ç´š L1

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Docetaxelè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/docetaxel/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_docetaxel,
  title = {Docetaxelè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/docetaxel/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
